Alexander Rogg

‘Forget all the reasons why it won’t work and believe the only reason why it will’. Working for Guardant Health. Tweets are reflecting my own point of view.

[Alexander Rogg @roggalex]

It’s #ASCO time!
I’m looking forward to seeing you at our Guardant Health booth #25077.

Let’s chat to learn more about how our liquid biopsies support healthcare systems around the world to transform cancer care.
https://t.co/nRFmruUj2B

#PatientsFirst 🧬🩸

[Sanjay Popat @DrSanjayPopat]

Delighted to share our data on upfront ctDNA testing in confirmed mNSCLC. Quicker genotyping, more information, faster decision making. #LSCM

[Guardant Health @GuardantHealth]

We're excited to announce our partnership with @royalmarsdenNHS to establish the first Guardant Health #liquidbiopsy testing service based in the United Kingdom for clinical research and clinical patient care.
https://t.co/dsRNU0aSHX

[International Society of Liquid Biopsy @isliquidbiopsy]

🔜The ISLB Annual Congress 2021
Will feature a fantastic lineup of
▶️LIVE🔴 SYMPOSIUMS
🗓️October 22nd 2021

Don't miss it!
FREE REGISTRATION👇
https://t.co/4nNm1V0Dze

@GuardantHealth
@menarini_es
@predicine
@NateraOncology

[Guardant Health @GuardantHealth]

Join experts @drgandara, Natasha Leighl, and @MDuruisseaux as they share the latest #liquidbiopsy advancements for #cancer and the value of the Guardant360 tests to support treatment decisions at the Annual @isliquidbiopsy Congress.
Register here: https://t.co/bpUrOsGiNo

[International Society of Liquid Biopsy @isliquidbiopsy]

🗣️The III Annual ISLB Congress, will like to thank
all the sponsors for their support to this international academic activity.
We invite you to visit all the virtual stands from
🗓️October 22nd 2021 at 8:00am CEST Time.

FREE Registration👇
https://t.co/DBwTpIm1Sa

[Alexander Rogg @roggalex]

#Cancer is a global threat that must be tackled #united!
Tomorrow @GuardantHealth joins the group of experts to discuss the #EUCancerPlan. It's our mission to put the #PatientsFirst enabling broad access to #GCP for all. https://t.co/L0YAoTaf5f
#PrecisionMedicine #BloodFirst

[Guardant Health @GuardantHealth]

Today we announced our Guardant360 CDx test received FDA approval as the first and only #liquidbiopsy companion diagnostic for @Amgen approved targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell #lungcancer. https://t.co/5ARVVuodfx

[Guardant Health @GuardantHealth]

The #USPSTF has updated their guidelines, lowering the #colorectalcancer screening age to 45 for people at average risk. We applaud the USPSTF and are hopeful that, along with efforts to achieve compliance, this can increase early detection and treatment. https://t.co/DrtwkI5OMp

[Guardant Health @GuardantHealth]

Our Guardant Reveal #liquidbiopsy test was approved by the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for the detection and monitoring of minimal residual disease #MRD in patients with early-stage cancer. https://t.co/HwUMc4NZnp

[Guardant Health @GuardantHealth]

We're committed to helping #colorectalcancer patients at all stages live longer, healthier lives. This #ColorectalCancerAwarenessMonth we celebrate the progress that's been made and strive toward continued advancements in testing and screening. #CRC #liquidbiopsy

[Guardant Health @GuardantHealth]

The pandemic has brought about health and economic crises that affect us all. We're proud to see our CEO stand beside leaders from 150 companies in a letter urging Congress to advance public health response to #COVID19 by passing the American Rescue Plan. https://t.co/awZY9Q2fWR

[Guardant Health @GuardantHealth]

"Scaling applies to people, not just companies." From
@AuthorityMgzine, read the recent interview with our CEO Helmy Eltoukhy on his career, advice for young founders, and how #liquidbiopsy is a big idea that can change the world. https://t.co/TgbMob4Ljp

[Guardant Health @GuardantHealth]

We’re excited to launch Guardant Reveal, the first blood-only #liquidbiopsy test for residual disease and recurrence monitoring of early-stage #colorectalcancer patients. #MRD https://t.co/3GsP9X1vgu

[Guardant Health @GuardantHealth]

This Wednesday at Liquid Biopsy for #PrecisionOncology Summit, join Guardant Health's VP of Outcomes and Evidence Kathryn Lang and Director of BD Patrick Eimerman for a discussion on Opportunities for #LiquidBiopsy Across the Continuum of Care. https://t.co/aKyhb1C2QI

[Guardant Health @GuardantHealth]

Together we can help improve outcomes for cancer patients across the continuum of care. Join us this #WorldCancerDay in raising awareness and committing to advances in #precisiononcology for patients at every stage of the disease. #IamandIwill https://t.co/okMhQHhbvb

[Guardant Health @GuardantHealth]

"35-44% of patients reported having their cancer care impacted." Happening now at #PMWC21: Watch the panel discussion on The Impact of COVID-19 on Cancer Care and Future Implications https://t.co/7ZnqoWYLhm
@PMWCintl

[Guardant Health @GuardantHealth]

"Cancer does not stop because we happen to be in a pandemic." Happening now at #PMWC21: Watch the panel discussion on The Impact of COVID-19 on Cancer Care and Future Implications https://t.co/7ZnqoWYLhm @PMWCintl

[Guardant Health @GuardantHealth]

"Significantly more genomic alterations can be detected with the Guardant360 #liquidbiopsy assay when used prior to tissue testing." Read more about the recent study published in JCO Precision Oncology: https://t.co/iM0d41Ttp3

[Guardant Health @GuardantHealth]

Together with @AstraZeneca @globalungcancer @IASLC our goal is to accelerate progress and drive forward meaningful improvements for people with #lungcancer. Join us in the #LungAmbition Alliance to help stop one of the most common cancers from claiming a life every 18 seconds.